Antonio C. Wolff

58.6k total citations · 11 hit papers
360 papers, 24.8k citations indexed

About

Antonio C. Wolff is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Antonio C. Wolff has authored 360 papers receiving a total of 24.8k indexed citations (citations by other indexed papers that have themselves been cited), including 257 papers in Oncology, 161 papers in Cancer Research and 110 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Antonio C. Wolff's work include Breast Cancer Treatment Studies (125 papers), HER2/EGFR in Cancer Research (94 papers) and Cancer Treatment and Pharmacology (81 papers). Antonio C. Wolff is often cited by papers focused on Breast Cancer Treatment Studies (125 papers), HER2/EGFR in Cancer Research (94 papers) and Cancer Treatment and Pharmacology (81 papers). Antonio C. Wolff collaborates with scholars based in United States, Germany and Canada. Antonio C. Wolff's co-authors include Mitch Dowsett, Lisa M. McShane, Kimberly H. Allison, Pamela B. Mangu, Giuseppe Viale, M. Elizabeth Hammond, Patrick L. Fitzgibbons, Daniel F. Hayes, Edith A. Perez and Patricia A. Spears and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Antonio C. Wolff

346 papers receiving 24.3k citations

Hit Papers

Recommendations for Human Epidermal Growth Factor Rec... 2005 2026 2012 2019 2013 2018 2005 2013 2018 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
    2013 3.1k citations Antonio C. Wolff, Edith A. Perez et al. Journal of Clinical Oncology profile →
  2. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
    2018 1.5k citations Antonio C. Wolff, Giuseppe Viale et al. Journal of Clinical Oncology profile →
  3. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
    2005 1.4k citations Gary H. Lyman, Mark R. Somerfield et al. Journal of Clinical Oncology profile →
  4. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
    2013 1.3k citations Antonio C. Wolff, Edith A. Perez et al. profile →
  5. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
    2018 1.0k citations Antonio C. Wolff, Giuseppe Viale et al. profile →
  6. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
    2014 953 citations Sylvia Adams, Robert J. Gray et al. Journal of Clinical Oncology profile →
  7. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
    2020 851 citations Lisa A. Carey, Daniel F. Hayes et al. Journal of Clinical Oncology profile →
  8. Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
    2008 672 citations Joseph A. Sparano, Molin Wang et al. profile →
  9. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
    2015 458 citations Beverly Moy, Antonio C. Wolff et al. profile →
  10. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
    2016 411 citations James N. Ingle, Antonio C. Wolff et al. profile →
  11. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update
    2023 251 citations Antonio C. Wolff, Mark R. Somerfield et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Antonio C. Wolff United States 71 15.9k 10.7k 5.5k 4.9k 3.9k 360 24.8k
Gϋnter von Minckwitz Germany 78 16.4k 1.0× 13.2k 1.2× 4.2k 0.8× 3.9k 0.8× 4.1k 1.0× 428 25.0k
Vicente Valero United States 94 17.3k 1.1× 13.2k 1.2× 5.4k 1.0× 4.9k 1.0× 2.9k 0.7× 500 27.9k
Fátima Cardoso Portugal 68 13.8k 0.9× 10.5k 1.0× 7.4k 1.3× 4.9k 1.0× 3.0k 0.8× 403 25.4k
Sibylle Loibl Germany 76 19.6k 1.2× 13.4k 1.3× 6.1k 1.1× 8.4k 1.7× 3.4k 0.8× 588 29.5k
Sandra M. Swain United States 66 15.4k 1.0× 7.2k 0.7× 5.1k 0.9× 4.8k 1.0× 4.9k 1.2× 337 23.4k
George W. Sledge United States 72 14.8k 0.9× 9.6k 0.9× 7.5k 1.4× 6.3k 1.3× 2.5k 0.6× 444 25.4k
Frédérique Penault‐Llorca France 57 10.8k 0.7× 7.1k 0.7× 5.4k 1.0× 4.4k 0.9× 3.2k 0.8× 335 18.7k
Edith A. Perez United States 79 20.7k 1.3× 11.1k 1.0× 6.6k 1.2× 5.8k 1.2× 4.4k 1.1× 400 30.1k
Lisa A. Carey United States 72 16.1k 1.0× 12.1k 1.1× 7.3k 1.3× 5.4k 1.1× 2.4k 0.6× 421 25.9k
Giuseppe Curigliano Italy 79 16.2k 1.0× 7.1k 0.7× 5.5k 1.0× 6.3k 1.3× 3.8k 1.0× 835 26.6k

Countries citing papers authored by Antonio C. Wolff

Since Specialization
Citations

This map shows the geographic impact of Antonio C. Wolff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio C. Wolff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio C. Wolff more than expected).

Fields of papers citing papers by Antonio C. Wolff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio C. Wolff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio C. Wolff. The network helps show where Antonio C. Wolff may publish in the future.

Co-authorship network of co-authors of Antonio C. Wolff

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio C. Wolff. A scholar is included among the top collaborators of Antonio C. Wolff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio C. Wolff. Antonio C. Wolff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
O’Brien, Barbara, Rashmi K. Murthy, Donald A. Berry, et al.. (2024). Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.. Journal of Clinical Oncology. 42(16_suppl). 2018–2018. 4 indexed citations
2.
Gatsonis, Constantine, Heather A. Jacene, Roisín M. Connolly, et al.. (2024). Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT trial.. Journal of Clinical Oncology. 42(16_suppl). TPS614–TPS614.
3.
Freedman, Rachel A., Jennifer L. Caswell‐Jin, Michael J. Hassett, et al.. (2024). Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology. 42(18). 2233–2235. 18 indexed citations
4.
Ballinger, Tarah J., Fengmin Zhao, Joseph A. Sparano, et al.. (2024). ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer.. Journal of Clinical Oncology. 42(17_suppl). LBA503–LBA503. 1 indexed citations
5.
6.
Lehmann, Brian D., Vandana G. Abramson, Elizabeth Claire Dees, et al.. (2023). Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer. JAMA Oncology. 10(2). 193–193. 18 indexed citations
7.
8.
Wallner, Lauren P., et al.. (2023). Physicians’ Hierarchy of Tumor Biomarkers for Optimizing Chemotherapy in Breast Cancer Care. The Oncologist. 29(1). e38–e46. 1 indexed citations
9.
10.
Visvanathan, Kala, Leslie Cope, Mary Jo Fackler, et al.. (2022). Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial. Clinical Cancer Research. 29(4). 784–790. 12 indexed citations
11.
Fackler, Mary Jo, Soonweng Cho, Leslie Cope, et al.. (2020). DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. npj Breast Cancer. 6(1). 3–3. 21 indexed citations
12.
Lehmann, Brian D., Vandana G. Abramson, Melinda E. Sanders, et al.. (2019). TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research. 26(9). 2111–2123. 113 indexed citations
13.
Paoletti, Costanza, Yufeng Li, Maria C. Muñiz, et al.. (2015). Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clinical Cancer Research. 21(12). 2771–2779. 75 indexed citations
14.
Mayer, Ingrid A., Christian F. Singer, Peter A. Fasching, et al.. (2015). A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HR+/HER2–, PIK3CA mutant or wild-type breast cancer.. Journal of Clinical Oncology. 1 indexed citations
15.
Fackler, Mary Jo, Zoila A. Lopez‐Bujanda, Christopher B. Umbricht, et al.. (2014). Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer. Cancer Research. 74(8). 2160–2170. 118 indexed citations
16.
Adams, Sylvia, Robert J. Gray, Sandra Demaria, et al.. (2014). Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. Journal of Clinical Oncology. 32(27). 2959–2966. 953 indexed citations breakdown →
17.
Wolff, Antonio C., Ann Lazar, Igor Bondarenko, et al.. (2012). Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology. 31(2). 195–202. 222 indexed citations
18.
Fackler, Mary Jo, Christopher B. Umbricht, Danielle Williams, et al.. (2011). Genome-wide Methylation Analysis Identifies Genes Specific to Breast Cancer Hormone Receptor Status and Risk of Recurrence. Cancer Research. 71(19). 6195–6207. 159 indexed citations
19.
Zellars, Richard C., Deborah A. Frassica, Vered Stearns, et al.. (2007). Phase I/II Trial of Partial Breast Irradiation With Concurrent Dose-Dense Doxorubicin and Cyclophosphamide (ddAC) Chemotherapy in Early Stage Breast Cancer: Report of Skin Toxicity and Cosmetic Outcome. International Journal of Radiation Oncology*Biology*Physics. 69(3). S26–S26. 2 indexed citations
20.
Wolff, Antonio C.. (2003). Liposomal Anthracyclines and New Treatment Approaches for Breast Cancer. The Oncologist. 8(S2). 25–30. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gϋnter von Minckwitz Breakdown of academic impact, for papers by Vicente Valero Breakdown of academic impact, for papers by Fátima Cardoso Breakdown of academic impact, for papers by Sibylle Loibl Breakdown of academic impact, for papers by Sandra M. Swain Breakdown of academic impact, for papers by George W. Sledge Breakdown of academic impact, for papers by Frédérique Penault‐Llorca Breakdown of academic impact, for papers by Edith A. Perez Breakdown of academic impact, for papers by Lisa A. Carey Breakdown of academic impact, for papers by Giuseppe Curigliano
Rankless by CCL
2026